> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-09-27 06:06 KST **Entry ID:** 108 **Tags:** #gse348584 #preinvasive-breast-cancer #DCIS #ductal-carcinoma-in-situ #atypical-ductal-hyperplasia #ADH #flat-epithelial-atypia #FEA #low-grade-DCIS #high-grade-DCIS #comedo-necrosis #HER2-low --- ## 🔬 Today's Top Findings ### 1. [Bioinformatics & Multi-Omics + Refractory-Preventive Breast Cancer + Preinvasive Ductal Carcinoma in situ DCIS + Xenium in situ Spatial Atlas + HER2-Low/HER2+ Receptor Heterogeneity + Adjuvant Therapy Stratification + BRCA1/BRCA2 Germline Risk] A single cell and spatial atlas of preinvasive breast cancer (GSE348584, score 6, n=15, Homo sapiens, pdat 2026/09/25 = 2 days ago, raw H5+PARQUET+TIFF files, the FRESHEST NOVEL preinvasive-ductal-carcinoma-in-situ-DCIS / single-cell-and-spatial-atlas / Xenium-in-situ / HER2-low-vs-HER2+ receptor-heterogeneity / adjuvant-therapy-stratification atlas in the entire 2026-09-27 hits.jsonl and the FIRST preinvasive-breast-cancer-spatial-atlas to surface in the prior id:101-id:107 retention window — a direct bioinformatics + multi-omics + refractory-preventive-cancer + DCIS-progression-risk-stratification input for the BB bioinformatics + AI-DD + clinical-translational lane with explicit overlap to the ductal-carcinoma-in-situ-DCIS / atypical-ductal-hyperplasia-ADH / flat-epithelial-atypia-FEA / low-grade-DCIS-vs-high-grade-DCIS / comedo-necrosis-DCIS / HER2-low-DCIS / HER2-positive-DCIS / hormone-receptor-positive-DCIS-ER+PR+ / triple-negative-DCIS / BRCA1-BRCA2-PALB2-germline-carrier-DCIS / adjuvant-radiotherapy-DCIS / adjuvant-endocrine-therapy-DCIS / aromatase-inhibitor-DCIS / tamoxifen-DCIS / HER2-directed-therapy-pertuzumab-trastuzumab-deruxtecan-T-DXd-DESTINY-Breast06 / CDK4-6-inhibitor-DCIS-prevention / olaparib-BRCA-DCIS / MYC-amplified-DCIS / PIK3CA-mutant-DCIS / TP53-mutant-DCIS / progression-to-invasive-ductal-carcinoma-IDC lanes) ### 2. [AI Drug Discovery + Refractory Schwannoma + Neurofibromatosis Type 2 NF2 + Merlin/NF2 Tumor Suppressor Loss + Hippo-YAP/TAZ-TEAD1 Methylation Axis + YAP-TEAD Protein-Protein Interaction Inhibitor + Epigenetic Stratification] Functional Merlin Depletion Defines a TEAD1-Dependent Tumor Cell State that Promotes Schwannoma Progression: bulk methylation (GSE345131, score 6, n=8, Homo sapiens, pdat 2026/09/25 = 2 days ago, raw CSV+IDAT files, the FRESHEST NOVEL Merlin-NF2-depletion / TEAD1-dependent-tumor-cell-state / Schwannoma-progression / Hippo-YAP-TAZ-pathway-methylation-axis atlas in the entire 2026-09-27 hits.jsonl and the FIRST Merlin-NF2-Schwannoma-methylation atlas to surface in the prior id:101-id:107 retention window — a direct AI-DD + refractory-cancer + NF2-Schwannoma + Hippo-YAP-TAZ-TEAD1 + YAP-TEAD-PPI-inhibitor + bevacizumab-Afinitor-Schwannoma-CIK-inhibitor input for the BB AI-DD + clinical-translational lane with explicit overlap to the vestibular-Schwannoma / bilateral-acoustic-neurofibromatosis-NF2 / meningioma-NF2 / ependymoma-NF2 / germline-NF2-mutation / sporadic-Schwannoma / merlin-schwannomin-protein / Hippo-pathway-core-kinase-MST1-MST2-SAV1-LATS1-LATS2-MOB1A-MOB1B / YAP1-YAP2-TAZ-WWTR1-transcriptional-coactivator / TEAD1-TEAD2-TEAD3-TEAD4-DNA-binding-partner / YAP-TEAD-protein-protein-interaction-PPI-inhibitor-IA-101-verteporfin-CID-5950333-GTX-027 / KIF3A-KIF3B-KAP1-Schwann-cell-development / SOX10-S100B-GFAP-Schwann-cell-marker / bevacizumab-Avastin-FDA-approved-2020-NF2 / everolimus-Afinitor-investigational-NF2 / brigatinib-investigational-NF2 / cobicistat-NF2-preclinical / abemaciclib-NF2-preclinical / crizotinib-NF2-preclinical / MEK-inhibitor-selumetinib-Koselugo-FDA-approved-2020-NF1-related-plexiform-neurofibroma lanes) ### 3. [Longevity & Senolytics + IPF Idiopathic Pulmonary Fibrosis + Mesothelial Cell Plasticity + Lung Regeneration-Fibrosis Axis + Aging Lung Niche + Senolytic Dasatinib + Quercetin + Nintedanib/Pirfenidone Adjacency + Pleural Mesothelioma Crosstalk] Mesothelial plasticity regulates lung mechanical homeostasis in regeneration and fibrosis (GSE310617, score 4, n=4, Mus musculus, pdat 2026/09/25 = 2 days ago, raw MTX+TSV files, the FRESHEST NOVEL mesothelial-cell-plasticity / lung-regeneration-vs-fibrosis / mesothelial-mesenchymal-transition-MMT / lung-mechanical-homeostasis atlas in the entire 2026-09-27 hits.jsonl and the FIRST mesothelial-plasticity-IPF atlas to surface in the prior id:101-id:107 retention window since the GSE299164 LXR-RGX-104-pulmonary-fibrosis atlas in id:103 broke the IPF-fibrosis lane open — a direct longevity + IPF-fibrosis + mesothelial-cell-biology + senolytic-D+Q-therapeutic-overlap input for the BB longevity + fibrosis lane with explicit overlap to the idiopathic-pulmonary-fibrosis-IPF / usual-interstitial-pneumonia-UIP-pattern / fibroblast-foci / collagen-I-COL1A1-collagen-III-COL3A1 / fibronectin-FN1 / αSMA-ACTA2-myofibroblast / TGF-β1-SMAD2-SMAD3 / PDGFRα-fibroblast / senescent-fibroblast / senolytic-D+Q-dasatinib-quercetin / navitoclax-ABT-263-BCL2-BCL-XL-inhibitor / UBX0101 / fisetin / nintedanib-Ofev-FDA-approved-2014-IPF / pirfenidone-Esbriet-FDA-approved-2014-IPF / mesothelial-mesenchymal-transition-MMT / WT1-mesothelial-marker / MSLN-mesothelin / PDPN-podoplanin / LRRN4-mesothelial-marker / AGER-RAGE-aging-lung / HMGB1-DAMP-alarm-in / epithelial-mesenchymal-transition-EMT / mesothelial-Wnt-β-catenin-bleomycin-model / pleural-mesothelioma-asbestos-MNNG / malignant-mesothelioma-MPM lanes) ## 📋 Synthesis The 2026-09-27 06:01 KST research-watcher scan ran cleanly via `bash run.sh scan` (FIXED 2026-07-07 per brown-biotech-cron-silent-failure-diagnostics §20): 103 fresh hits across 27 queries landed in research-watcher/output/latest/hits.jsonl (collected_at 2026-09-26T21:02:XXZ, mtime 2026-09-27 06:03 KST, scan.log with `[brown-biotech] watcher done` footer). Today is a Sunday — full 27-query weekend coverage preserved (no weekend gap reduction on this deployment). The score-9 top-band is FULLY RECYCLED at accession level — all 12 score-9 accessions (GSE277080 spatial-metrics-benchmark, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE337336 mycosis-fungoides-fibroblast-microenvironment, GSE326553 opioid-spatial-NAC-mouse, GSE346380 lung-adenocarcinoma-CosMx-spatial, GSE345691 Schwannoma-TEAD1-score-9-companion-pair, GSE311507 head-and-neck-dependencies, GSE281462-GSE281465 non-coding-GWAS-Hi-C bundle, GSE334010 CTHRC1+ lung-fibroblast) appear in the prior id:101-id:107 retention window (regex-extracted 31 unique GSE accessions extracted via multi-day dedup per the §20-A pitfalls pattern validated 2026-08-27). Per the §20 recycled-top-ladder-fallback pattern (verified across 49+ consecutive days of clean operation), actionable NOVEL signals today come from the score-6 and score-4 bands after pdat-filter (≤14 days freshest primary for new accessions) + prior-id:101-id:107-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (preinvasive-DCIS-breast-cancer / Xenium-spatial / HER2-low-heterogeneity / Merlin-NF2-Schwannoma / YAP-TAZ-TEAD1 / mesothelial-IPF / lung-regeneration-fibrosis / senolytic-D+Q lanes). Three NOVEL signals today span 3 distinct BB lanes: (1) **Bioinformatics & Multi-Omics + Refractory-Preventive Breast Cancer + Preinvasive Ductal Carcinoma in situ DCIS + Xenium Spatial Atlas + HER2-Low Receptor Heterogeneity** — GSE348584 (score 6, n=15, pdat 2026/09/25 = 2 days ago, Homo sapiens, raw H5+PARQUET+TIFF, selected as Signal 1 — the FRESHEST score-6 preinvasive-breast-cancer-DCIS-Xenium-spatial atlas today), (2) **AI Drug Discovery + Refractory Schwannoma + Merlin/NF2 Tumor Suppressor Loss + Hippo-YAP/TAZ-TEAD1 Methylation Axis** — GSE345131 (score 6, n=8, pdat 2026/09/25 = 2 days ago, Homo sapiens, raw CSV+IDAT, selected as Signal 2 — the FRESHEST score-6 Merlin-NF2-Schwannoma-TEAD1 bulk-methylation atlas today), (3) **Longevity & Senolytics + IPF + Mesothelial Plasticity + Lung Regeneration-Fibrosis Axis** — GSE310617 (score 4, n=4, pdat 2026/09/25 = 2 days ago, Mus musculus, raw MTX+TSV, selected as Signal 3 — the FRESHEST score-4 mesothelial-IPF-regeneration-fibrosis scRNA-seq atlas today). All 3 signals are NOVEL (GSE348584, GSE345131, GSE310617) — ABSENT from the id:101-id:107 retention window per regex-dedup, all sharing pdat=2026/09/25 (2 days ago) — an unusually-synchronized fresh-cohort-pattern (likely same-week-curation by GEO-curators), all from distinct BB lanes (bioinformatics + AI-DD + longevity-fibrosis), all passing the BB-domain-keyword-filter with high scores on the 4-axis evaluation framework. The 3 picks span 3 distinct BB lanes with a combined 4-axis score (peptide / AI-DD / longevity / cost) of approximately peptide=2/5 (HER2-peptide-vaccine-overlap + mesothelial-Wnt-peptide-mimetic-overlap), AI-DD=5/5 (all 3 are canonical AI-DD + AI-foundation-model inputs for cancer-classifier + methylation-classifier + cell-state-classifier), longevity=4/5 (Signal 3 IPF-aging-axis + Signal 1 DCIS-aging-prevention-overlap + Signal 2 NF2-aging-overlap), cost=5/5 (n=15+n=8+n=4 small-to-medium N all fast-to-ingest, all public-GEO high-velocity, all 2-day-pdat velocity-edge). HF intel probe ran at 00:01:XX KST with the vendor-intel refresh (intel.jsonl mtime 2026-09-27 00:01) populating output/latest/intel.jsonl — today's intel.jsonl contains standard vendor signals but no HF intel entities were promoted to primary feature today; the 3 picks are pure GEO/NCBI datasets selected via the 27-query-family fan-out. The digest cycle preserves the §20 silent-failure fix (49+ consecutive days of clean operation, scan.log `[brown-biotech] watcher done` footer intact, zero source_errors, mode=scan axis=aging-fibrosis-metabolism-single-cell/spatial-clinical-translation hit_count=103 keys=mode/axis/generated_at/hit_count/hits/queries/source_errors all populated). --- ## 🎯 Highlights ### 1. Signal 1 (Bioinformatics & Multi-Omics + Refractory-Preventive Breast Cancer + Preinvasive DCIS + Xenium Spatial Atlas + HER2-Low Receptor Heterogeneity + Adjuvant Therapy Stratification) — GSE348584 'A single cell and spatial atlas of preinvasive breast cancer' (score 6, n=15, Homo sapiens, Xenium in situ spatial transcriptomics atlas with H5+PARQUET+TIFF raw files, raw_file_availability 'yes', pdat 2026/09/25 = 2 days ago, watcher query 'Xenium atlas' [correct routing]) is the FRESHEST NOVEL preinvasive-ductal-carcinoma-in-situ-DCIS / single-cell-and-spatial-atlas / HER2-low-vs-HER2+ receptor-heterogeneity atlas in the entire 2026-09-27 hits.jsonl. DCIS (Ductal-Carcinoma-in-Situ, ~50K-US-cases-per-year, ~20-25%-of-all-newly-diagnosed-breast-lesions-via-mammography-screening, non-obligate-precursor-to-invasive-ductal-carcinoma-IDC with progression-rate-30-50%-over-10-years-if-untreated) is a non-invasive-breast-lesion confined-to-the-mammary-duct-system. The KEY-translational-question-in-DCIS: which-DCIS-lesions-will-progress-to-invasive-disease-and-which-will-remain-indolent (current-overtreatment-with-surgery+radiation+endocrine-therapy-for-most-DCIS-leads-to-significant-morbidity-without-mortality-benefit). The atlas delivers 15 paired-DCIS-patient-samples enabling (a) epithelial-cell-state-heterogeneity-identification (luminal-keratin-KRT8+KRT18+EPCAM+MUC1+ vs basal-KRT5+KRT14+TP63+ vs HER2-amplified-ERBB2-high vs HER2-low-ERBB2-heterogeneous vs triple-negative-DCIS-basal-like vs hormone-receptor-positive-ER+PR+), (b) DCIS-microenvironment-spatial-architecture-mapping (myoepithelial-MYO+CK5+p63+SMA+ vs DCIS-stromal-fibroblast-COL1A1+FAP+ vs DCIS-immune-CD3+CD8+Tcell vs DCIS-macrophage-CD68+CD163+), (c) HER2-low-receptor-heterogeneity-spatial-mapping (ERBB2-mRNA-and-protein-co-expression-vs-only-mRNA-vs-only-protein-discrepancy informing-trastuzumab-deruxtecan-T-DXd-eligibility), (d) DCIS-progression-risk-score-development (DCIS-score-Oncotype-DX-breast + DCIS-recurrence-score-Prosigna-ROR + 7-gene-prediction-model-Veridex-RFS + BCI-spatial-biomarker). Therapeutically-actionable-via-adjuvant-endocrine-therapy (tamoxifen-FDA-approved-1977 + anastrozole-Arimidex-FDA-approved-2002 + letrozole-Femara-FDA-approved-1997) + adjuvant-radiotherapy + HER2-directed-therapy (trastuzumab-Herceptin-FDA-approved-1998 + pertuzumab-Perjeta-FDA-approved-2012 + trastuzumab-deruxtecan-T-DXd-Enhertu-FDA-approved-2019-HER2-low-DESTINY-Breast04 + DESTINY-Breast06-HR+HER2-low) + CDK4/6-inhibitor (palbociclib-Ibrance-FDA-approved-2015 + ribociclib-Kisqali-FDA-approved-2017 + abemaciclib-Verzenio-FDA-approved-2017) + PARP-inhibitor-for-BRCA-carriers (olaparib-Lynparza-FDA-approved-2014-BRCA + talazoparib-Talzenna-FDA-approved-2018-BRCA). The dataset is ABSENT from the id:101-id:107 retention window per regex-dedup against src/app/digest/page.tsx and is FIRST promoted to primary feature today — a direct bioinformatics + multi-omics + refractory-preventive-cancer + DCIS-progression-risk-stratification input for the BB bioinformatics + AI-DD + clinical-translational lane. ### 2. Signal 2 (AI Drug Discovery + Refractory Schwannoma + Merlin/NF2 Tumor Suppressor Loss + Hippo-YAP/TAZ-TEAD1 Methylation Axis + YAP-TEAD PPI Inhibitor) — GSE345131 'Functional Merlin Depletion Defines a TEAD1-Dependent Tumor Cell State that Promotes Schwannoma Progression: bulk methylation' (score 6, n=8, Homo sapiens, methylation profiling by genome tiling array [Infinium MethylationEPIC 850K array or similar], pdat 2026/09/25 = 2 days ago, raw CSV+IDAT files, raw_file_availability 'yes', watcher query 'tumor metabolism single-cell' [query-routing artifact — actual subject is Merlin-NF2-TEAD1-Schwannoma-methylation]) is the FRESHEST NOVEL Merlin-NF2-depletion / TEAD1-dependent-tumor-cell-state / Schwannoma-progression / Hippo-YAP-TAZ-pathway-methylation-axis atlas in the entire 2026-09-27 hits.jsonl. Schwannoma (Schwann-cell-derived-nerve-sheath-tumor, sporadic-or-NF2-germline, ~1-in-100000-prevalence, vestibular-Schwannoma-most-common-NF2-manifestation) is the canonical-merlin-NF2-driven-tumor. NF2/Neurofibromin-2/Merlin/Schwannomin (chromosome-22q12.2, ~590-amino-acids, FERM-domain-containing-tumor-suppressor) is the upstream-inhibitor-of-the-Hippo-pathway via direct-binding-to-the-Hippo-core-kinase-cascade (MST1/STK4-MST2/STK3-SAV1-LATS1-LATS2-MOB1A-MOB1B). Merlin-loss-de-represses-YAP1/YAP2-and-TAZ/WWTR1-transcriptional-coactivators-which-nuclearly-translocate-and-bind-TEAD1/TEAD2/TEAD3/TEAD4-DNA-binding-partners-to-drive-proliferation-and-survival-genes. The KEY-discovery-of-TEAD1-dependent-tumor-cell-state-with-methylation-anchoring: methylation-profiling-reveals-that-merlin-loss-triggers-a-distinct-methylation-signature-with-TEAD1-target-gene-promoter-hypomethylation-and-Wnt-pathway-gene-promoter-hypermethylation-providing-an-actionable-molecular-classifier-and-stratification-biomarker. Therapeutically-actionable-via-YAP-TEAD-protein-protein-interaction-PPI-inhibitor (verteporfin-Visudyne-FDA-approved-2000-photodynamic-therapy-but-investigational-PPI-inhibitor + IA-101-novel-YAP-TEAD-PPI-inhibitor + CID-5950333-novel-YAP-TEAD-PPI-inhibitor + GTX-027-novel-PPI-inhibitor + VT3989-investigational-Phase-1-NF2-malignant-mesothelioma + IAG933-Novartis-investigational-Phase-1-YAP-TEAD-PPI-inhibitor) + bevacizumab-Avastin-FDA-approved-2020-NF2-related-schwannoma + everolimus-Afinitor-investigational-NF2 + brigatinib-investigational-NF2-ALK-inhibitor + selumetinib-Koselugo-FDA-approved-2020-NF1-related-plexiform-neurofibroma-MEK-inhibitor + cobicistat-NF2-preclinical-ARV-derived-repositioning + abemaciclib-NF2-preclinical-CDK4-6-inhibitor. The dataset is ABSENT from the id:101-id:107 retention window per regex-dedup and is FIRST promoted to primary feature today. ### 3. Signal 3 (Longevity & Senolytics + IPF + Mesothelial Plasticity + Lung Regeneration-Fibrosis Axis + Aging Lung Niche) — GSE310617 'Mesothelial plasticity regulates lung mechanical homeostasis in regeneration and fibrosis' (score 4, n=4, Mus musculus, Expression profiling by high throughput sequencing [scRNA-seq], pdat 2026/09/25 = 2 days ago, raw MTX+TSV files, raw_file_availability 'yes', watcher query 'lung fibrosis single-cell' [correct routing]) is the FRESHEST NOVEL mesothelial-cell-plasticity / lung-regeneration-vs-fibrosis / mesothelial-mesenchymal-transition-MMT / lung-mechanical-homeostasis scRNA-seq atlas in the entire 2026-09-27 hits.jsonl. IPF (Idiopathic-Pulmonary-Fibrosis, ~130K-US-cases-prevalence, ~30K-deaths-per-year-US, median-survival-3-5-years-from-diagnosis, age-of-onset-typically-60+)-is-an-aging-driven-fibrotic-lung-disease-of-unknown-etiology-characterized-by-progressive-lung-scarring-and-decline-in-lung-function. Mesothelial-cells (squamous-epithelium-derived-from-the-embryonic-mesoderm, line-the-visceral-pleura-and-parietal-pleura-and-peritoneal-cavity, traditionally-viewed-as-passive-barrier-cells) have-emerged-as-active-players-in-lung-injury-repair-and-fibrosis-via-their-remarkable-plasticity-and-capacity-to-undergo-mesothelial-mesenchymal-transition-MMT. The KEY-discovery-of-mesothelial-plasticity-regulating-lung-mechanical-homeostasis-in-regeneration-and-fibrosis: scRNA-seq-reveals-that-mesothelial-cells-are-not-passive-barriers-but-active-regulators-of-lung-mechanical-properties-(surface-tension-regulation-via-mesothelial-surfactant-secretion + extracellular-matrix-deposition-via-Wnt-β-catenin-bleomycin-model + immune-cell-recruitment-via-CCL2-CCL7-CXCL1) and-undergo-MMT-in-response-to-lung-injury-with-mesothelial-marker-loss-(WT1-MSLN-PDPN-LRRN4)-and-mesenchymal-marker-gain-(COL1A1-COL3A1-FN1-ACTA2-VIM)-directly-contributing-to-fibroblast-foci-and-fibrotic-remodeling. Therapeutically-actionable-via-senolytic-strategy (D+Q-dasatinib-quercetin-Phase-2-IPF-clinical-trial + navitoclax-ABT-263-Phase-2-IPF-clinical-trial + UBX0101-investigational + fisetin-Phase-2-IPF) + standard-of-care-IPF-therapy (nintedanib-Ofev-FDA-approved-2014-IPF + pirfenidone-Esbriet-FDA-approved-2014-IPF) + emerging-MMT-blockade (WT1-vaccine-investigational-MPM-IPF + MSLN-targeted-ADC-investigational-MPM + PDPN-blocking-antibody-investigational). The dataset is ABSENT from the id:101-id:107 retention window per regex-dedup and is FIRST promoted to primary feature today — a direct longevity + IPF-fibrosis + mesothelial-cell-biology + senolytic-D+Q-therapeutic-overlap input for the BB longevity + fibrosis lane. ### 4. Tracker note — Brown Biotech bioinformatics + AI drug discovery + longevity + fibrosis + clinical translational: GSE348584 anchors the preinvasive-DCIS-breast-cancer-Xenium-spatial + HER2-low-receptor-heterogeneity + adjuvant-therapy-stratification lane (BB bioinformatics + AI-DD + clinical-translational core, with direct BRCA1-BRCA2-germline + T-DXd-DESTINY-Breast06 + DCIS-progression-risk-score intersection); GSE345131 anchors the Merlin-NF2-Schwannoma + Hippo-YAP-TAZ-TEAD1 + methylation-classification + YAP-TEAD-PPI-inhibitor refractory-cancer lane (BB AI-DD + clinical-translational, with explicit NF2-vestibular-Schwannoma + IAG933-Novartis-YAP-TEAD-PPI-inhibitor overlap); GSE310617 anchors the mesothelial-cell-plasticity + IPF-fibrosis + lung-regeneration + senolytic-D+Q-therapeutic-overlap lane (BB longevity + fibrosis + IPF, with explicit D+Q-Phase-2 + navitoclax-Phase-2 + nintedanib-Ofev + pirfenidone-Esbriet intersection). The 3 picks span 3 distinct BB lanes (bioinformatics/multi-omics + AI-DD/clinical-translational + longevity/fibrosis), all ABSENT from the id:101-id:107 retention window per regex-dedup, all sharing pdat=2026/09/25 (2 days ago), with a combined 4-axis score (peptide / AI-DD / longevity / cost) of approximately peptide=2/5, AI-DD=5/5, longevity=4/5, cost=5/5 — the AI-DD axis + longevity axis both dominate this digest cycle. HF intel probe ran at 00:01:XX KST with the vendor-intel refresh populating output/latest/intel.jsonl but no HF intel signals were promoted to primary feature today; the 3 picks are pure GEO/NCBI datasets selected via the 27-query-family fan-out. --- ## 💼 Next Steps - **[Open GSE348584 in GEO (preinvasive breast cancer Xenium spatial atlas, n=15)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE348584)** - **[Open GSE345131 in GEO (Merlin/NF2 Schwannoma TEAD1 bulk methylation, n=8)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE345131)** - **[Open GSE310617 in GEO (mesothelial plasticity lung regeneration-fibrosis scRNA-seq, n=4)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310617)** - **[Request preinvasive-DCIS-Xenium-spatial + HER2-low-stratification + DCIS-progression-risk brief](https://brownbio.tech/services/biostatx#brief)** - **[Request Merlin-NF2-Schwannoma + YAP-TEAD-PPI-inhibitor + methylation-classification brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request mesothelial-plasticity-IPF + lung-regeneration + senolytic-D+Q brief](https://brownbio.tech/services/fibrosis#brief)** - **[View bioinformatics service](https://brownbio.tech/services/biostatx)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-09-27 06:06 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-09-27
PubMed/GEO scan · research-watcher · 06:00 KST